{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Untreated&page=55", "query": { "condition": "Untreated", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 1385, "total_pages": 139, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Untreated&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Untreated&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T05:54:06.827Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00443300", "title": "Effectiveness of Protected Environment Rooms for AML and MDS", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 3, "start_date": "2007-01", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2012-08-02", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00443300" }, { "nct_id": "NCT01010945", "title": "Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-02-03", "completion_date": "2012-01-25", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 5, "location_summary": "Palm Springs, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010945" }, { "nct_id": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "MEDI5752", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "AZD2936", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 175, "start_date": "2018-12-27", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819465" }, { "nct_id": "NCT00085839", "title": "Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Tarceva (Trademark) (erlotinib HCl, OSI-774)", "type": "DRUG" }, { "name": "Combination carboplatin and paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2004-02", "completion_date": "2007-03", "has_results": true, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 19, "location_summary": "Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085839" }, { "nct_id": "NCT05077800", "title": "FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "FOLFIRNINOX", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colin D. Weekes, M.D., PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-03-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 4, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077800" }, { "nct_id": "NCT00005964", "title": "Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 59, "start_date": "2000-05", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005964" }, { "nct_id": "NCT00219934", "title": "Observational Study of Treated and Untreated Acute and Early HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Antiretroviral therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 399, "start_date": "2002-02", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-02-17", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00219934" }, { "nct_id": "NCT00251433", "title": "GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib, docetaxel, trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2005-09-26", "completion_date": "2022-06-22", "has_results": false, "last_update_posted_date": "2023-03-31", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251433" }, { "nct_id": "NCT01555268", "title": "Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "trebananib", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-10-31", "completion_date": "2016-08-03", "has_results": false, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 2, "location_summary": "Buffalo, New York • Rochester, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555268" }, { "nct_id": "NCT00544674", "title": "PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "PR104", "type": "DRUG" }, { "name": "F-18-fluoromisonidazole", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Proacta, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-08", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2012-12-10", "last_synced_at": "2026-10-24T05:54:06.827Z", "location_count": 18, "location_summary": "Tucson, Arizona • Beverly Hills, California • Greenbrae, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544674" } ] }